Molecular diagnostics equipment provider Myriad Genetics has agreed to acquire US-based precision medicine developer Assurex Health in a deal that will enable Mayo Clinic and Cincinnati Children’s Hospital Medical Center to exit.
Myriad will pay $225m upfront and could provide up to $185m in performance-based milestones.
Assurex’s lead product, GeneSight Psychotropic, evaluates 12 genes that play a role in psychotropic drug response and, using pharmacogenomics, assigns patients into unique phenotypes and accordingly recommends suitable psychotropic drug treatments.
The deal will…
